Geode Capital Management LLC Purchases 52,506 Shares of CVS Health Corporation $CVS

Geode Capital Management LLC lifted its position in shares of CVS Health Corporation (NYSE:CVS) by 0.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 29,040,271 shares of the pharmacy operator’s stock after buying an additional 52,506 shares during the period. Geode Capital Management LLC’s holdings in CVS Health were worth $2,294,689,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in CVS. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares during the period. Ares Financial Consulting LLC bought a new position in CVS Health in the 4th quarter valued at approximately $29,000. Dogwood Wealth Management LLC lifted its stake in CVS Health by 93.7% in the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 179 shares during the last quarter. GoalVest Advisory LLC bought a new position in CVS Health in the 4th quarter valued at approximately $32,000. Finally, Financial Consulate Inc. lifted its stake in CVS Health by 99.6% in the 4th quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator’s stock valued at $40,000 after purchasing an additional 249 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Insider Buying and Selling at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,441,551 shares of company stock valued at $323,703,977 in the last ninety days. Insiders own 0.85% of the company’s stock.

CVS Health Price Performance

CVS stock opened at $92.95 on Friday. The company has a fifty day moving average price of $81.71 and a 200-day moving average price of $79.47. The company has a market capitalization of $118.59 billion, a P/E ratio of 40.95, a PEG ratio of 0.90 and a beta of 0.60. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $98.43. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts expect that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s weight-loss drug Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could improve member access and make CVS’s drug formularies more competitive. Article Title
• Positive Sentiment: CVS Health Ventures led a $40 million investment in H1, reinforcing CVS’s push into health-tech and AI-driven provider data accuracy, which could support long-term digital growth initiatives. Article Title
• Positive Sentiment: Aetna launched “Aetna Mental Health On Demand,” giving members faster access to mental-health care and adding another visible example of CVS expanding its integrated care offerings. Article Title
• Positive Sentiment: CVS also expanded its Salesforce partnership to improve call-center service with AI tools, which may lower friction for members and providers and improve operating efficiency. Article Title
• Neutral Sentiment: Several reports focused on CVS’s dividend safety, with commentary suggesting the payout remains covered by cash flow; this is reassuring for income investors, but it is not a direct catalyst. Article Title
• Negative Sentiment: CVS filed suit to challenge Tennessee’s new PBM-pharmacy breakup law, signaling regulatory and legal pressure on part of its business model; however, this is more of a risk factor than an immediate earnings driver. Article Title

Analyst Ratings Changes

Several equities analysts recently commented on CVS shares. Weiss Ratings reissued a “hold (c)” rating on shares of CVS Health in a research note on Friday, May 8th. The Goldman Sachs Group increased their price objective on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Piper Sandler dropped their price objective on shares of CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a research note on Tuesday, March 31st. Morgan Stanley increased their price objective on shares of CVS Health from $93.00 to $106.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Finally, Leerink Partners reissued an “outperform” rating and issued a $98.00 price objective on shares of CVS Health in a research note on Thursday, March 5th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.88.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.